FCRL1 immunoregulation in B cell development and malignancy

Frontiers in Immunology

Immunology

Ran Li¹  Edlue M. Tabengwa¹  Kazuhito Honjo¹  Murali K. Mamidi¹  Jifeng Huang¹  Randall S. Davis²  Marko Radic³  Nar’asha L. Randall³  Manasa V. Ponnuchetty³  Indira Neeli³  Chuen-Miin Leu⁴ 

[1] Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States;Departments of Microbiology, and Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, United States;O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States;Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States;Institute of Microbiology and Immunology, National Yang Ming ChiaoTung University, Taipei, Taiwan;

关键词: FCRL1;    B cells;    lymphocyte development;    B cell receptor;    signaling;    malignancy;    immunotherapy;   

DOI  :  10.3389/fimmu.2023.1251127

 received in 2023-06-30, accepted in 2023-09-01,  发布年份 2023

来源: Frontiers

【 摘 要 】

Immunotherapeutic targeting of surface regulatory proteins and pharmacologic inhibition of critical signaling pathways has dramatically shifted our approach to the care of individuals with B cell malignancies. This evolution in therapy reflects the central role of the B cell receptor (BCR) signaling complex and its co-receptors in the pathogenesis of B lineage leukemias and lymphomas. Members of the Fc receptor-like gene family (FCRL1-6) encode cell surface receptors with complex tyrosine-based regulation that are preferentially expressed by B cells. Among them, FCRL1 expression peaks on naïve and memory B cells and is unique in terms of its intracellular co-activation potential. Recent studies in human and mouse models indicate that FCRL1 contributes to the formation of the BCR signalosome, modulates B cell signaling, and promotes humoral responses. Progress in understanding its regulatory properties, along with evidence for its over-expression by mature B cell leukemias and lymphomas, collectively imply important yet unmet opportunities for FCRL1 in B cell development and transformation. Here we review recent advances in FCRL1 biology and highlight its emerging significance as a promising biomarker and therapeutic target in B cell lymphoproliferative disorders.

【 授权许可】

Unknown   
Copyright © 2023 Mamidi, Huang, Honjo, Li, Tabengwa, Neeli, Randall, Ponnuchetty, Radic, Leu and Davis